Physician profile
Michael P Farrell
NPI 1841396959
$1,945.68
in general payments reported to CMS, 2019-2025
16 companies · $282 in 2025
The $282 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $1,056 · 2021: $32.47 · 2022: $18.20 · 2023: $41.14 · 2024: $74.53 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $397.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mckesson Specialty Care Distribution, LLC | $1,238.48 | 2019-2020 | |
| Celgene Corporation | $122.49 | 2024-2025 | Reblozyl |
| Sanofi-Aventis U.S. LLC | $99.95 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $94.61 | 2022-2025 | Opdivo |
| Genentech USA, INC. | $84.73 | 2020-2025 | Itovebi, Phesgo, Perjeta |
| Merck Sharp & Dohme LLC | $46.26 | 2019-2020 | |
| Daiichi Sankyo INC. | $41.20 | 2024-2025 | Enhertu |
| Janssen Biotech, INC. | $35.74 | 2025 | Tecvayli, Darzalex |
| Ipsen Biopharmaceuticals, INC | $34.31 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $29.97 | 2019 | |
| Glaxosmithkline, LLC. | $24.57 | 2025 | Ojjaara |
| Astrazeneca Pharmaceuticals LP | $24.30 | 2024 | Tagrisso |
| Coherus Oncology, INC. | $23.36 | 2020 | |
| Astellas Pharma US INC | $21.50 | 2023 | Padcev |
| Seagen INC. | $12.29 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Farrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.